海爾生物(688139.SH):2024年淨利潤3.67億元 同比下降9.71%
格隆匯2月27日丨海爾生物(688139.SH)公佈2024年度業績快報,2024年公司營業收入228,383.29萬元,恢復正向增長;通過積極應對外部環境挑戰,報告期內業務發展呈現向好態勢。同比來看,繼第三季度營業收入增速轉正後,第四季度增速進一步提升至10.40%,且國內與海外市場、存儲與非存儲產業在第四季度全部實現增長。環比來看,儘管第四季度部分訂單的交付存在跨期情況,但從訂單增長上季度間持續改善的態勢明確。歸屬於母公司所有者的淨利潤36,663.28萬元,同比下降9.71%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.